Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jacques Miller, M. Sadelain (2015)The journey from discoveries in fundamental immunology to cancer immunotherapy.
Cancer cell, 27 4
A. Morales, D. Eidinger, A. Bruce (2002)Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976.
The Journal of urology, 167 2 Pt 2
D. Dhawan, M. Paoloni, Shweta Shukradas, D. Choudhury, B. Craig, J. Ramos-Vara, N. Hahn, P. Bonney, C. Khanna, D. Knapp (2015)Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer
PLoS ONE, 10
(1976)Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors
J Urol, 116
P. Sharma, S. Hu-Lieskovan, J. Wargo, A. Ribas (2017)Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Weihui Liu, Ya-Yu Chen, Shao-xing Zhu, Yi-Ning Li, Yipeng Xu, Xuejing Wu, Yi-hong Guo, Jia-Liang Wang (2014)B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms
Oncology Letters, 8
Min Fan, Qianfeng Zhuang, Yiming Chen, T. Ding, H. Yao, Lujun Chen, Xiaozhou He, Xianlin Xu (2014)B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma.
International journal of clinical and experimental pathology, 7 10
D. Knapp, J. Ramos-Vara, G. Moore, D. Dhawan, P. Bonney, Kirsten Young (2014)Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.
ILAR journal, 55 1
A. Sankin, D. Narasimhulu, P. John, B. Gartrell, M. Schoenberg, X. Zang (2017)The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Urologic oncology, 36 10
Christopher Fulkerson, D. Dhawan, T. Ratliff, N. Hahn, D. Knapp (2017)Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs
International Journal of Genomics, 2017
D. Prasad, S. Richards, X. Mai, C. Dong (2003)B7S1, a novel B7 family member that negatively regulates T cell activation.
Immunity, 18 6
A. Apolo, A. Mortazavi, M. Stein, S. Pal, N. Davarpanah, H. Parnes, Y. Ning, D. Francis, L. Cordes, P. Monk, Tiffany Lancaster, R. Costello, S. Nanda, D. Bottaro, J. Wright, H. Streicher, S. Steinberg, M. Berninger, L. Lindenberg, W. Dahut (2017)A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
Journal of Clinical Oncology, 35
J. Smith, Evripidis Lanitis, D. Dangaj, E. Buza, M. Poussin, Caitlin Stashwick, N. Scholler, D. Powell (2016)Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Molecular therapy : the journal of the American Society of Gene Therapy, 24 11
J. Coy, A. Caldwell, L. Chow, A. Guth, S. Dow (2017)PD‐1 expression by canine T cells and functional effects of PD‐1 blockade
Veterinary and Comparative Oncology, 15
D. Dangaj, Evripidis Lanitis, Aizhi Zhao, Shree Joshi, Yi Cheng, R. Sandaltzopoulos, H. Ra, G. Danet-Desnoyers, D. Powell, N. Scholler (2013)Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Cancer research, 73 15
M. Paoloni, C. Khanna (2008)Translation of new cancer treatments from pet dogs to humans
Nature Reviews Cancer, 8
A Phase1/2,Open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors
M. Boegemann, A. Aydin, A. Bagrodia, L. Krabbe (2017)Prospects and progress of immunotherapy for bladder cancer
Expert Opinion on Biological Therapy, 17
K. Ohaegbulam, Weifeng Liu, Hyungjun Jeon, S. Almo, X. Zang (2017)Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells
X. Zang, J. Allison (2007)The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Clinical Cancer Research, 13
X. Zang, R. Thompson, H. Al-Ahmadie, H. Al-Ahmadie, A. Serio, V. Reuter, J. Eastham, P. Scardino, P. Sharma, J. Allison (2007)B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Proceedings of the National Academy of Sciences, 104
Tian Zhou, A. Sankin, S. Porcelli, D. Perlin, M. Schoenberg, X. Zang (2017)A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Urologic oncology, 35 1
C. Khanna, K. Lindblad-Toh, D. Vail, C. London, P. Bergman, L. Barber, M. Breen, B. Kitchell, Elizabeth McNeil, J. Modiano, S. Niemi, K. Comstock, E. Ostrander, S. Westmoreland, S. Withrow (2006)The dog as a cancer model
Nature Biotechnology, 24
X. Zang, P. Loke, Jayon Kim, K. Murphy, R. Waitz, J. Allison (2003)B7x: A widely expressed B7 family member that inhibits T cell activation
Proceedings of the National Academy of Sciences of the United States of America, 100
D. Dhawan, N. Hahn, J. Ramos-Vara, D. Knapp (2018)Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer
PLoS Genetics, 14
M. Janakiram, U. Shah, Weifeng Liu, A. Zhao, M. Schoenberg, X. Zang (2017)The third group of the B7‐CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7‐H3
Immunological Reviews, 276
E. Brunskill, S. Potter (2012)RNA-Seq defines novel genes, RNA processing patterns and enhancer maps for the early stages of nephrogenesis: Hox supergenes.
Developmental biology, 368 1
G. Sica, I. Choi, G. Zhu, K. Tamada, Shengxi Wang, H. Tamura, A. Chapoval, D. Flies, J. Bajorath, Lieping Chen (2003)B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.
Immunity, 18 6
Joanne Leung, P. St-Onge, J. Stagg, Woong-Kyung Suh (2017)Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model
Cancer Immunology, Immunotherapy, 66
Hyungjun Jeon, V. Vigdorovich, Sarah Garrett-Thomson, M. Janakiram, U. Ramagopal, Yael Abadi, Jun Lee, L. Scandiuzzi, K. Ohaegbulam, Jordan Chinai, Ruihua Zhao, Yu Yao, Y. Mao, J. Sparano, S. Almo, X. Zang (2014)Structure and cancer immunotherapy of the B7 family member B7x.
Cell reports, 9 3
N. Maekawa, S. Konnai, R. Ikebuchi, T. Okagawa, M. Adachi, S. Takagi, Y. Kagawa, C. Nakajima, Yasuhiko Suzuki, S. Murata, K. Ohashi (2014)Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
PLoS ONE, 9
Background:B7x (B7-H4/B7S1/VTCN1), an inhibitory immune checkpoint molecule is a potential therapeutic target owing to its immunosuppressive effect and well-known expression in cancers. Immune checkpoints in canine bladder cancer are largely undefined. Here, we report the first evaluation on expression of B7x in spontaneous canine invasive bladder cancer, a novel model system for the study of invasive human urothelial carcinoma.Objective:This work aims to study expression of immune checkpoint B7x in spontaneous canine invasive bladder cancer.Methods:RNA-seq analysis was performed to determine B7x expression in tumor versus normal bladder. Gene ontology (GO) study was used to explore the biological role of B7x. B7x protein expression was evaluated by immunohistochemistry (IHC). TCGA and GTEx were used to examine B7x expression in 599 human bladder urothelial carcinoma (BLCA).Results:RNA-seq analysis indicated 5.72 and 7.04 fold up regulation of B7x in tumors, using DESeq2 and edge R respectively (p < 0.00008). B7x was closely associated with immune processes in GO analysis. IHC results revealed 60% of cases as B7x positive. B7x intensity was scored as negative in 40% (n = 20/50), low in 24% (n = 12/50), medium in 14% (n = 7/50) and high in 22% (n = 11/50) of cases. In human BLCA, B7x expression was significantly associated with worse overall survival (p = 0.02).Conclusions:Our results suggest that B7x is over expressed in canine bladder cancer. Thus canine model can be vital in advancing the translational research on B7x, a new potential therapeutic target in human bladder cancer.
Bladder Cancer – IOS Press
Published: Jan 1, 2019
Access the full text.
Sign up today, get DeepDyve free for 14 days.